Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Ahmad Masri, MD, MS

Director, Hypertrophic Cardiomyopathy Center
Director, Cardiac Amyloidosis Program
Assistant Professor of Medicine
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Disclosures

Disclosure: Ahmad Masri, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: Attralus; Bridgebio; Bristol Myers Squibb; Cytokinetics; Ionis; Tenaya
Research funding from: Akcea; Ionis; Pfizer; Ultromics

Anjali Tiku Owens, MD

Medical Director
Center for Inherited Cardiac Disease
Assistant Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Disclosure: Anjali Tiku Owens, MD, has the following relevant financial relationships:
Consultant or advisor for: Cytokinetics; MyoKardia/Bristol Myers Squibb; Pfizer
Research funding from: Cytokinetics; Myokardia/Bristol Myers Squibb; Pfizer

Omar Wever-Pinzon, MD

Director Inherited Cardiomyopathy Program
Assistant Professor of Medicine
University of Utah Health Sciences Center
Division of Cardiology
Heart Failure and Transplant
Salt Lake City, Utah

Disclosures

Disclosure: Omar Wever-Pinzon, MD, has the following relevant financial relationships:
Consultant or advisor for: Tenaya Pharmaceuticals
Speaker or member of speakers bureau for: Bristol Myers Squibb

Editors

Joy P. Marko, MS, APN-C, CCMEP

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

Asha P. Gupta, PharmD, RPh

Associate Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.

Renata Feldman, PharmD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Renata Feldman, PharmD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

CME

Hypertrophic Cardiomyopathy Mini Lessons: New Perspectives for the Evolving Treatment Paradigm

Authors: Ahmad Masri, MD, MS; Anjali Tiku Owens, MD; Omar Wever-Pinzon, MD
CME Released: 5/24/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/24/2023, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, and surgeons.

The goal of this activity is that learners will be better able to increase awareness of the underlying disease mechanisms of HCM and the specific role of muscle biology, including the latest data and implications, to attenuate contractility and improve patient outcomes.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Molecular rationale for disease-modifying therapies in HCM
- Current data for the use of cardiac myosin inhibition for the treatment of HCM
- Emerging data for the use of cardiac myosin inhibition for the treatment of HCM
- Identification of patients who may benefit from cardiac myosin inhibition therapy

Disclosures

Faculty

Ahmad Masri, MD, MS

Director, Hypertrophic Cardiomyopathy Center
Director, Cardiac Amyloidosis Program
Assistant Professor of Medicine
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Disclosures

Disclosure: Ahmad Masri, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: Attralus; Bridgebio; Bristol Myers Squibb; Cytokinetics; Ionis; Tenaya
Research funding from: Akcea; Ionis; Pfizer; Ultromics

Anjali Tiku Owens, MD

Medical Director
Center for Inherited Cardiac Disease
Assistant Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Disclosure: Anjali Tiku Owens, MD, has the following relevant financial relationships:
Consultant or advisor for: Cytokinetics; MyoKardia/Bristol Myers Squibb; Pfizer
Research funding from: Cytokinetics; Myokardia/Bristol Myers Squibb; Pfizer

Omar Wever-Pinzon, MD

Director Inherited Cardiomyopathy Program
Assistant Professor of Medicine
University of Utah Health Sciences Center
Division of Cardiology
Heart Failure and Transplant
Salt Lake City, Utah

Disclosures

Disclosure: Omar Wever-Pinzon, MD, has the following relevant financial relationships:
Consultant or advisor for: Tenaya Pharmaceuticals
Speaker or member of speakers bureau for: Bristol Myers Squibb

Editors

Joy P. Marko, MS, APN-C, CCMEP

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

Asha P. Gupta, PharmD, RPh

Associate Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.

Renata Feldman, PharmD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Renata Feldman, PharmD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME

Hypertrophic Cardiomyopathy Mini Lessons: New Perspectives for the Evolving Treatment Paradigm

Authors: Ahmad Masri, MD, MS; Anjali Tiku Owens, MD; Omar Wever-Pinzon, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 5/24/2022

Valid for credit through: 5/24/2023, 11:59 PM EST

processing....

Select Any Chapter to Begin

Clinician Handout

Page 1 of 25

Sarcomere Dysfunction in HCM: Dissecting the Therapeutic Target - Pre-Assessment

CME Information

Activity Transcript

PDF Downloads

Clinician Handout

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Ahmad Masri, MD, MS

Anjali Tiku Owens, MD

Omar Wever-Pinzon, MD

Editors

Joy P. Marko, MS, APN-C, CCMEP

Asha P. Gupta, PharmD, RPh

Renata Feldman, PharmD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

CME

Hypertrophic Cardiomyopathy Mini Lessons: New Perspectives for the Evolving Treatment Paradigm

Target Audience and Goal Statement

Disclosures

Faculty

Ahmad Masri, MD, MS

Anjali Tiku Owens, MD

Omar Wever-Pinzon, MD

Editors

Joy P. Marko, MS, APN-C, CCMEP

Asha P. Gupta, PharmD, RPh

Renata Feldman, PharmD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Hypertrophic Cardiomyopathy Mini Lessons: New Perspectives for the Evolving Treatment Paradigm

Select Any Chapter to Begin

Clinician Handout

PDF Downloads